You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

11 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Adjuvant, Curative
May 2019
Cancer Type: Gynecologic, Cervix     
Intent: Curative
Jan 2018
Cancer Type: Breast, Central Nervous System, Gastrointestinal, Colorectal, Esophagus, Gastric / Stomach, Hepatobiliary / Liver / Bile Duct, Pancreas, Genitourinary, Bladder / Urothelial, Prostate, Gynecologic, Cervix, Endometrial, Ovary, Head and Neck, Lung, Small Cell     
Intent: Adjuvant, Curative, Palliative
May 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Curative, Adjuvant
May 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative, Palliative
Nov 2017
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
May 2019
Cancer Type: Sarcoma, Desmoid Tumour     
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019